What the FDA labels say about taking them together
Glycopyrrolate and remifentanil
Remifentanil's FDA label of December 15, 2025 names glycopyrrolate in its warnings and precautions section; the glycopyrrolate labels PlainMeds reads (4) do not name remifentanil.
Check it at the source: the glycopyrrolate FDA label on DailyMed (effective October 9, 2025, Hikma Pharmaceuticals USA Inc.); the remifentanil FDA label on DailyMed (effective December 15, 2025, Mylan Institutional LLC).
What does the glycopyrrolate label say about remifentanil?
Glycopyrrolate's label (effective October 9, 2025) and its 3 other brand-application labels do not name remifentanil in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Glycopyrrolate), Hikma Pharmaceuticals USA Inc., effective October 9, 2025 (SPL set 960d2dd0-008d-4ec1-ba2e-9388b28b23e2), via openFDA; the full label on DailyMed
What does the remifentanil label say about glycopyrrolate?
Remifentanil label, warnings and precautionsBradycardia has been reported with ULTIVA and is responsive to ephedrine or anticholinergic drugs, such as atropine and glycopyrrolate.
Source: FDA drug label (Ultiva), Mylan Institutional LLC, effective December 15, 2025 (SPL set 4dbcb8f9-1987-4b66-bd2f-d251fda0be10), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glycopyrrolate | Remifentanil | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.51 per mL 0.2 mg/mL vial | n/a |
| Shortage now | A presentation being discontinued | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once